Introduction
Despite improvements in overall survival and clinical responses of unprecedented duration with the use of therapeutic monoclonal antibodies that target programmed cell death -1 (PD-1) or programmed cell Research.
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Author Manuscript Published OnlineFirst on May 17, 2018; DOI: 10.1158/2159-8290.CD-18-0099 death -1 ligand (PD-L1), the majority of patients with non-small cell lung cancer (NSCLC) fail to respond to PD-1/PD-L1 axis inhibitors (1-8). The landscape of primary resistance to PD-1 blockade in NSCLC is largely unknown, with no single factor capable of accurately segregating responders from nonresponders. Expression of PD-L1 on the membrane of tumor and immune cells is associated with enhanced objective response rates to PD-1/PD-L1 inhibition, but is neither sensitive nor specific (1- 3, 7, [9] [10] [11] [12] . A higher burden of non-synonymous somatic mutations (tumor mutation burden; TMB) further correlates with increased likelihood of clinical benefit and is undergoing evaluation as a predictive biomarker in many tumor types (4, (13) (14) (15) .
KRAS mutations are the most prevalent oncogenic driver in NSCLC, accounting for ~25% of LUAC (16, 17) . We previously reported that co-occurring genomic alterations in the STK11/LKB1 (KL) and TP53 (KP) tumor suppressor genes define subgroups of KRAS-mutant LUAC with distinct biology, therapeutic vulnerabilities and immune profiles (18). STK11/LKB1 encodes a serine threonine kinase with an established role in the regulation of cellular metabolism/energy homeostasis, growth and polarity through phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and 12 AMPKrelated kinases (19) . Inactivation of STK11 (or its protein product, LKB1) by mutational or nonmutational mechanisms is associated with an inert or "cold" tumor immune microenvironment, with reduced density of infiltrating cytotoxic CD8+ T lymphocytes in both human tumors and genetically engineered murine models (18, 20, 21) . Based on these findings, we hypothesized that STK11/LKB1 genomic alterations may predict for lack of clinical benefit from PD-1/PD-L1 blockade in KRAS-mutant LUAC and conducted a study to address this hypothesis and examine the inter-relationship between individual genetic alterations, TMB and PD-L1 expression.
Results

Patient characteristics
Research.
Author Manuscript Published OnlineFirst on May 17, 2018; DOI: 10.1158/2159-8290.CD-18-0099 174 patients that met the pre-specified eligibility criteria were included in the SU2C dataset [MDACC (N=62), MSKCC (N=56), DFCI/MGH (N=56)] ( Table 1 ). The overall cohort was representative of the general population of patients with KRAS-mutant LUAC with median patient age of 66 years (range , high percentage of current/former smokers (88.5%) and typical frequencies of distinct KRAS-mutant alleles (Figure S1A and S1B) (16) (17) (18) 22) . Across the entire cohort, 31 % of tumors were classified as KL, 32% were KP and 37% K-only ( Figure S1C ). The majority of patients received PD-1 inhibitor monotherapy (165/174, 95%) and the remainder received combination with CTLA-4 blockade (9/174, 5%) ( Figure S1A ).
Demographic and clinical characteristics were generally well balanced between the co-mutation defined subgroups ( Figure S1A and Figure S1D ). STK11/LKB1 mutations were in their overwhelming majority predicted to be deleterious ( Figure S2 ).
Co-mutations in STK11/LKB1 are associated with inferior clinical outcome with PD-1 blockade in multiple independent cohorts of KRAS-mutant LUAC.
The objective response rates to PD-1 inhibition in KL, KP and K-only groups were significantly different (P<0.001, Fisher's exact test) ( Figure 1A and Figure 1C ). KL tumors were mostly resistant to PD-1 axis blockade (ORR 7.4% overall), with consistently low response rates seen in each of the three independent datasets (MDACC: 9.1%, MSKCC: 9.1%, DFCI/MGH: 4.8%). In contrast, KP LUAC were more sensitive to PD-1 inhibitors (ORR 35.7% overall). K-only tumors with no identifiable mutations in either STK11/LKB1 or TP53 had an intermediate response rate (28.6%). Assessment of additional co-occurring genetic alterations in the few KL tumors that responded to PD-1 blockade did not identify any obvious unifying molecular features ( Figure S3 ).
In order to replicate these findings in the context of a randomized clinical trial, we further analyzed the impact of STK11/LKB1 and TP53 genetic alterations on clinical outcomes in 44 patients with KRASmutant NSCLC (96% LUAC) with available WES data that were randomly assigned to treatment with Research.
on September 1, 2018. © 2018 American Association for Cancer cancerdiscovery.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. nivolumab (N=24) or docetaxel (N=20) in the CheckMate-057 randomized phase 3 clinical trial (NCT01673867). In agreement with data from the SU2C cohort, ORR differed significantly between the KL, KP and K-only subgroups in the nivolumab arm of CM-057 (P=0.047), with KL tumors being refractory (ORR: 0%, 0/6) and KP more sensitive (ORR: 57.1%, 4/7) to nivolumab ( Figure 1B) . Although ORR did not differ significantly between the three subgroups in the docetaxel arm (P=0.65), it is relevant to note that the ORR in the KL subgroup was 0% (0/3) [ORR was 0% (0/6) and 18.2% (2/11) in KP and K only subgroups, respectively]. Given the relatively small numbers within subgroups, it cannot be determined whether STK11/LKB1 mutation is prognostic or predictive of treatment outcomes in the CM-057 dataset.
Progression-free survival differed between the three groups in the SU2C cohort (P=0.0018), with significantly shorter PFS for patients with KL compared to either KP (HR 1.77, 95% CI 1.16-2.69; P=0.0072) or K-only tumors (HR 1.98, 95% CI 1.33-2.94; P<0.001) in pair-wise comparisons (Figure 2A , left panel). In contrast, patients with KP and K-only tumors had similar PFS. Because STK11/LKB1 abrogation likely determines immunotherapy resistance in this context, we further compared PFS in patients with STK11/LKB1 wild-type and mutant tumors by merging the KP and K-only cohorts. PFS was significantly shorter in KL tumors compared to KRAS-mutant LUAC with wild-type STK11/LKB1 (HR 1.87, 95% CI 1.32 to 2.66; P<0.001) ( Figure 2A , right panel). The CM-057 study had limited power to detect PFS or OS differences due to the small size of subgroup cohorts and no significant differences were seen in PFS or OS in either arm ( Figure S4 and Figure S5 ).
Overall survival also varied significantly between the three groups in the SU2C cohort (P=0.0045) ( Figure   2B , left panel). Median overall survival was 6.4 months in KL compared with 16.0 months in KP and 16.1 months in K-only LUACs. In the two group comparison, overall survival was significantly shorter in STK11/LKB1-mutant compared to wild-type tumors (HR 1.99, 95% CI 1.29 to 3.06; P=0.0015) ( Figure 2B , right panel). KRAS subgroup remained a significant independent predictor of OS on multivariate analysis (P=0.00055). Notably, STK11/LKB1 mutation or deficiency were not associated with worse OS in the TCGA cohort, arguing against a purely prognostic role for STK11/LKB1 inactivation in this setting of predominantly early stage, surgically resected tumors ( Figure S6 ), in agreement with previous studies in metastatic tumors (23) (24) (25) .
Because non-mutational mechanisms can also account for STK11/LKB1 inactivation in LUAC (19), we further assessed expression of LKB1 (the protein product of the STK11 gene) by IHC in a subset of tumors for which archival tissue was available (26). KRAS MUT ;STK11/LKB1 MUT (KL) tumors expressed low to undetectable levels of LKB1 whereas KRAS MUT ;STK11/LKB1 WT tumors displayed variable levels of LKB1 expression, with 17.6% having a LKB1 H-score of zero ( Figure 3A ). Patients bearing STK11/LKB1-deficient tumors (STK11/LKB1 MUT or STK11/LKB1 WT and LKB1 H-score zero) exhibited significantly shorter PFS (HR 1.80, 95%CI 1.15-2.82; P=0.0094) ( Figure 3B In a parallel, unbiased analysis, we sought to identify candidate genomic drivers of absent PD-L1 expression (as an indicator of a "cold" or non-T-cell inflamed immune microenvironment) in LUAC using the large FM dataset ( Figure S7 ). We focused on TMB intermediate and high (TMB I/H ) tumors and excluded TMB low (TMB L ) LUAC since low TMB has been associated with impaired response to PD-1 axis inhibitors in retrospective studies, likely due to poor tumor immunogenicity (4, 13) . We then compared Figure   4B ). Furthermore, STK11 /LKB1 was significantly enriched (P<0.001) for PD-L1 Neg ; TMB I/H negative status even when the analysis was restricted to KRAS-mutant samples. Thus, we conclude that STK11/LKB1 is associated with higher likelihood of absent PD-L1 expression among TMB I/H tumors irrespective of KRAS status.
We further analyzed PD-L1 expression and TMB in the KL/KP/K-only subgroups and their KRAS wild-type counterparts ( Figure 4C and Figure S8 ). PD-L1 expression varied significantly between the KRAS subgroups ( Figure 4C , P < 0.001), with KL least likely to be PD-L1 HP (P < 0.001) ( Figure S8 ). Among KRAS wildtype tumors STK11/LKB1 alterations were also associated with lower likelihood of high PD-L1 expression ( Figure S8 ). KP LUAC exhibited the highest rate of PD-L1 positivity (56.3% PD-L1-positive, 31.3% PD-L1 HP ) followed by the TP53-altered, KRAS-wild-type group (32.3% PD-L1-positive, 11% PD-L1 HP ) ( Figure S8 ). In contrast, median TMBs across samples with KRAS, STK11/LKB1or TP53 alterations were comparable, ranging between 8.1 and 11.7 mutations/Mb ( Figure 4D and Figure S8 ).
Consistent with the observed association between STK11/LKB1 genomic alterations and low PD-L1
expression in the FM cohort, significant difference in the rate of PD-L1 positivity (PD-L1≥1%) was also noted between KL, KP and K-only tumors in the SU2C and CheckMate-057 cohorts ( Figure 4C and Figure   S9 ), with KL exhibiting the lowest frequency of PD-L1-positive (13.6% in the SU2C and 11.1% in the CM-057 cohort) and PD-L1 HP tumors (0% in both cohorts) ( Figure 4C and Figure S9 ).
We further directly interrogated the composition of the tumor immune microenvironment in surgically resected LUAC specimens (PROSPECT cohort) with available whole exome sequencing and automated quantitative IHC-based immune profiling (27, 28) . In agreement with lower tumor cell PD-L1 expression, STK11/LKB1-mutated tumors exhibited lower densities of infiltrating CD3+ (P=0.0019) and CD8+ (P=0.0072) T-lymphocytes but not FOXP3+ cells (P=0.7648) ( Figure S10A ). Furthermore, in the TCGA Research.
Author Manuscript Published OnlineFirst on May 17, 2018; DOI: 10.1158/2159-8290.CD-18-0099 dataset STK11/LKB1-mutated LUAC (or STK11/LKB1-deficient LUAC as determined using a previously validated gene expression signature (29)) exhibited lower T-cell signature scores (30) ( Figure S10B ) and expressed lower PD-L1 (CD274) mRNA levels ( Figure S10C ). Thus, we provide compelling evidence from multiple independent cohorts that STK11/LKB1 genomic alterations are associated with, and may actually promote, a non-T-cell-inflamed immune microenvironment with lack of tumor cell PD-L1 expression, despite an intermediate or high TMB.
STK11/LKB1 genomic alterations are associated with primary resistance to PD-1 axis inhibitors in PD-
L1 positive NSCLC
In view of the strong association between STK11/LKB1 genomic alterations and lack of PD-L1 expression on tumor cells, we also sought to examine the impact of STK11/LKB1 mutations on clinical responses to PD-1 axis blockade in PD-L1 positive (≥1%) non-squamous NSCLC. For this analysis, we identified a distinct cohort of 66 non-squamous NSCLC patients (irrespective of KRAS status) treated with PD-1/PD-L1 inhibitors at MDACC, with available STK11/LKB1 genomic profiling and PD-L1 expression (assessed using the FDA-approved 22C3 pharmDx assay). Within this PD-L1-positive group, STK11/LKB1-mutated tumors exhibited significantly lower ORR to PD-1/PD-L1 blockade compared to NSCLC with intact STK11/LKB1 (ORR 0% vs 34.5%, P=0.026, Fisher's exact test) ( Figure 5A ), despite inclusion of PD-L1 highexpressing tumors in the STK11/LKB1-mutant group ( Figure 5B ). Importantly, STK11/LKB1 mutations were associated with dramatically shorter PFS (HR 4.76, 95%CI 2.0-11.1, P=0.00012, log rank test) and OS (HR 14.3, 95% CI 3.4-50.0, P<0.0001, log-rank test) with PD-1 axis blockade ( Figure 5C and Figure 5D ).
The effect of STK11/LKB1 genomic alterations on PFS and OS with PD-1/PD-L1 blockade did not differ significantly across PD-L1 high (PD-L1≥50%) and low (PD-L1<50%) expressing groups (interaction test; P=0.48 for PFS and P=0.59 for OS) ( Figure S11 ). We therefore conclude that STK11/LKB1 genomic alterations impact response to PD-1/PD-L1 blockade at least partially independently of PD-L1 status and that their effect likely extends to the entire population of non-squamous NSCLC regardless of KRAS Research.
status. Extension of the effect of STK11/LKB1 inactivation to the broader population of non-squamous
NSCLC is further supported by data from a separate cohort of TMB I/H non-squamous NSCLC patients (without available PD-L1 expression) treated with anti-PD-1/PD-L1 therapy, whereby STK11/LKB1 alterations (regardless of KRAS status) were associated with significantly shorter time on drug (HR 2.91, 95% CI 1.22-6.92; P=0.0156) ( Figure S12 ).
TP53 co-mutations may impact response to PD-1 inhibitors in PD-L1 negative KRAS-mutant LUAC.
As part of an exploratory analysis we interrogated the impact of KRAS co-mutations on clinical benefit from PD-1 blockade in PD-L1-negative tumors. Among PD-L1-negative KRAS-mutant LUAC in the SU2C cohort (n=46), DCR differed significantly between the subgroups (P=0.034) and was highest (70%) in KP tumors ( Figure S13 ). The difference in ORR also favored the KP subgroup (30%), but did not reach statistical significance (P=0.11, Figure S13 ). This result further supports the notion that the predictive utility of co-mutations may extend beyond that of PD-L1 expression.
Stk11/Lkb1 ablation induces de novo resistance to PD-1 blockade in a syngeneic murine model of
KRAS-mutant LUAC.
In order to establish whether primary resistance to immunotherapy is causally linked with STK11/LKB1 inactivation we generated Stk11/Lkb1 proficient/deficient isogenic derivatives of the LKR13 Kras-mutant LKR13KO tumors compared to their Stk11/Lkb1-proficient counterparts, whereas numbers of CD45+ and CD3+CD4+ cells were not significantly different ( Figure S15 ). Furthermore, we did not observe enrichment of tumor associated neutrophils in the microenvironment of Stk11/Lkb1-deficient tumors in this model ( Figure S15 ), contrary to a previous report (20) . Similar results were obtained using a second syngeneic tumor model based on the LKR10 Kras-mutant murine LUAC cell line in response to treatment with anti-PD-1 mAb or isotype control ( Figure 6B ). Thus, Stk11/Lkb1 loss directly promotes primary resistance to PD-1/PD-L1 blockade and fosters establishment of a non-T-cell-inflamed tumor immune microenvironment in immune competent murine models of KRAS-mutant LUAC.
Discussion
In this study we identify genomic alterations in STK11/LKB1 as a tumor cell-intrinsic determinant of primary resistance to PD-1 axis blockade in three independent retrospective cohorts of KRAS-mutant LUAC, a fourth cohort of PD-L1-positive NSCLC regardless of KRAS status, as well as in patients with KRAS-mutant NSCLC treated with nivolumab in the pivotal CheckMate-057 randomized phase 3 clinical trial. Somatic mutations in STK11/LKB1 are prevalent in LUAC (16.7% in the large FM cohort), particularly among KRAS-mutant tumors (25.4% in the combined FM/SU2C cohort) and foster establishment of a non-T-cell-inflamed tumor immune microenvironment with frequently undetectable tumor cell PD-L1 expression (18, 20, 21) . Furthermore, we show that genetic ablation of Stk11/Lkb1 directly promotes resistance to anti-PD-1/anti-PD-L1 therapy in two immune competent Kras-mutant LUAC murine models. Therefore, STK11/LKB1 inactivation represents a major driver of immune escape and innate resistance to PD-1 blockade in KRAS-mutant LUAC.
Our work demonstrates that alterations in STK11/LKB1 are associated with lack of PD-L1 expression in tumor cells across multiple independent cohorts, despite the presence of intermediate or high TMB. This finding is consistent with lower densities of infiltrating CD8+ cytotoxic T lymphocytes in both human and murine STK11/LKB1 deficient tumors. However, the negative impact of STK11/LKB1 genomic alterations on clinical response to PD-1 axis inhibitors also extends to PD-L1-positive NSCLC, indicating that it is at least partially independent of PD-L1 expression. In addition, in an exploratory analysis among PD-L1negative KRAS-mutant LUAC, KP tumors exhibited more favorable response to PD-L1 blockade, with PR/SD achieved in 7/10 patients. Therefore, analysis of STK11/LKB1 and TP53 co-mutations may help refine response prediction algorithms in both PD-L1 positive and negative tumors as well as in cases where tumor biopsy for assessment of PD-L1 expression is unavailable or impractical but profiling of ctDNA ("liquid biopsy") has been obtained.
It is important to note that non-mutational mechanisms may also account for STK11/LKB1 inactivation in a subset of LUAC (19). Quantitative IHC for LKB1 (the protein product of the STK11 gene) can capture STK11/LKB1-deficient tumors in the absence of STK11/LKB1 genomic alterations (26). Therefore, TGFβ signaling (36), that has also been shown to be subject to modulation by STK11/LKB1 (37) . Furthermore, loss of PTEN (phosphatase and tensin homologue), that -similar to STK11/LKB1 alterations -results in mTOR pathway activation, has been associated with impaired CD8+ T-cell recruitment in melanoma (38) . In this tumor type, prior seminal work highlighted active WNT/β-catenin signaling as a key molecular driver of the non-T-cell-inflamed phenotype, via ATF3-mediated suppression of CCL4 production and impaired recruitment of CD103+ dendritic cells to the tumor immune microenvironment (30); interestingly, STK11/LKB1 deficiency has previously been associated with WNT pathway activation (39) . Finally, it was recently demonstrated that tumor cell-derived prostaglandin E2 (PGE2) can also impair recruitment of conventional type 1 dendritic cells (cDC1) to the tumor microenvironment both directly, through down-regulation of chemokine receptor expression in cDC1, and indirectly, via attenuation of NK cell viability and function (40) . It was previously reported that expression of cyclooxygenase-2 (COX-2) -that catalyzes the conversion of arachidonic acid to prostaglandins -is enhanced in STK11/LKB1 deficient NSCLC cells via activated CRTC1 (CREB-regulated transcription co-activator 1) (41) . Thus, multiple and potentially non-overlapping mechanisms may In contrast, evidence of pre-existing CD8+ T-cell infiltrate and adaptive immune resistance in the majority of KP (and possibly K-only STK11/LKB1-proficient) tumors supports simultaneous targeting of multiple immune inhibitory pathways in this subgroup (43) .
Taken together, our data reveal a novel, frequent driver of de novo resistance to PD-1 blockade in KRASmutant LUAC and potentially the entire LUAC population. More broadly, somatic genomic alterations in individual genes may modulate the efficacy of PD-1/PD-L1 inhibitors in given tumor types and across tumor types. Although the fully integrated set of determinants of response to these agents is not yet completely defined, our results suggest that the development of tailored immunotherapy approaches for NSCLC may be facilitated by genomic profiling to allow simultaneous characterization of specific somatic alterations including KRAS, STK11/LKB1, and TP53, in addition to TMB and PD-L1 expression. 
Methods
Patients
Study assessments
Tumor response was assessed by dedicated thoracic radiologists (MDACC, MSKCC, DFCI) or the study investigators (MGH) using Response Evaluation Criteria in Solid Tumors, version 1.1 (RECISTv1.1).
Objective response rate (ORR) was defined as the percentage of patients achieving a confirmed or unconfirmed complete or partial response. Attribution of stable disease as best overall response to therapy required a minimum interval of ≥ 30 days between the first day of the first cycle of treatment (C1D1) and radiological evaluation. Patients who died before radiological re-assessment were deemed to have progressive disease. Progression-free survival (PFS) was defined as the time from C1D1 to the date of disease progression or death from any cause. Overall survival (OS) was defined as the time from C1D1 to the date of death from any cause. Efficacy endpoints for patients included in CM-057 were evaluated as previously described (46) .
In the SU2C cohort, tumor cell PD-L1 expression was assessed in the most recent pre-immunotherapy formalin-fixed paraffin-embedded tumor biopsy tissue at each institution using the PD-L1 E1L3N® XP® rabbit monoclonal antibody (Cell Signaling Technology), and quantified as the percent of tumor cell membranes exhibiting specific staining of any intensity. PD-L1 expression in CM-057 samples was assessed using the validated 28-8 pharmDx assay (Dako, Carpinteria, CA) (3). PD-L1 staining of tumor samples submitted to FM was performed using the VENTANA PD-L1 (SP142) assay. Tumors were characterized as PD-L1 negative (PD-L1 < 1%), low positive (1% ≤ PD-L1 < 50%), or high positive (PD-L1 ≥ 50%). Assessment of PD-L1 expression in the separate cohort from MDACC (N=66) was based on the FDA-approved 22C3 pharmDx assay (Dako, Carpinteria, CA).
Molecular profiling platforms and study group definitions
Research. CGP of tumor and/or circulating cell free tumor DNA utilized CLIA-certified assays available in each of the participating institutions (47) (48) (49) (50) (51) (52) . Samples from CM-057 underwent whole exome sequencing according to previously described methodology (4) . Samples submitted to FM were processed at a CLIAcertified laboratory as previously described (53). TMB was measured by FM as previously described (54).
Raw TMB values were measured in units of mutations per Mb and characterized as low (TMB<6), intermediate (6 ≤TMB<20), or high (TMB≥20). 
KRAS-mutant
Statistical analysis
The significance of the association between the KL, KP, and K-only subgroup allocations and objective response to PD-1 axis blockade was assessed using Fisher's exact test. The Kaplan-Meier method was used to estimate PFS and OS. For the analysis of PFS, data for patients who were alive and had no evidence of disease progression at the time of the PFS data lockout (31 st of December 2016) or who were lost to follow up were censored at the time of the last radiological tumor assessment. For the analysis of OS, data for patients who were alive or lost to follow up at the time of the OS data lockout Wald test was applied for testing the hazard ratio of 1. A p value of ≤0.05 was considered statistically significant for all comparisons, unless stated otherwise.
Analysis of clinical endpoints in CM-057 was conducted as previously described and corresponds to a February 18, 2016 database lock (46) .
For TMB and PD-L1 analysis, statistics were calculated using R version 3.3.2 (2016-10-31). The enrichment analysis for LUAC in the PD-L1/TMB landscape was limited to genes altered in >1% of samples (100 genes).
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